Open AccessPhase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Author(s) -
Julie R. Gralow,
William E. Barlow,
Alexander Paterson,
Jieling Miao,
Danika Lew,
Alison Stopeck,
Daniel F. Hayes,
Dawn L. Hershman,
Mark M. Schubert,
Mark Clemons,
Catherine Van Poznak,
Elizabeth Claire Dees,
James N. Ingle,
Carla Falkson,
Anthony Elias,
Michael J. Messino,
Jeffrey Margolis,
Shaker R. Dakhil,
Helen K. Chew,
Kim Z Dammann,
Jeffrey S. Abrams,
Robert B. Livingston,
Gabriel N. Hortobágyi
Publication year - 2019
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djz215
Subject(s) - medicine , zoledronic acid , breast cancer , oncology , clinical endpoint , adjuvant therapy , adjuvant , confidence interval , randomized controlled trial , cancer
Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer.